Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:3 Issue:4 Number:75 ISSN#:2563-5476
ACE Report #6213
Ace Report Cover General Orthopaedics

WCO-IOF: Rituximab for rheumatoid arthritis positively impacts BMD of femoral neck

How to Cite

OrthoEvidence. WCO-IOF: Rituximab for rheumatoid arthritis positively impacts BMD of femoral neck. ACE Report. 2014;3(4):75. Available from: https://myorthoevidence.com/AceReport/Report/6213

Study Type:Randomized Trial
OE Level Evidence:N/A
Journal Level of Evidence:N/A

The effect of rituximab therapy on bone mineral density with rheumatoid arthritis patients

Contributing Authors: MV Koroleva TA Raskina

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.


92 patients diagnosed with rheumatoid arthritis (RA) were randomized to receive methotrexate with or without rituximab therapy to assess the impact of rituximab treatment on bone mineral density (BMD) at the femoral neck. BMD and T-scores significantly increased after 3 years in patients who received methotrexate and rituximab therapy, and maintained positive trends at the 4-year follow-up. No sig...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

For Reprints and Permissions, click here

Please Login or Join to leave comments.